✦ LIBER ✦

Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α

✍ Scribed by Yang, S; de Souza, P; Alemao, E; Purvis, J

Book ID: 110000441
Publisher: Nature Publishing Group
Year: 2010
Tongue: English
Weight: 246 KB
Volume: 102
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6605647

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Temsirolimus in patients with advanced r

Temsirolimus in patients with advanced renal cell carcinoma: an overview

✍ Shailender Bhatia; John A. Thompson 📂 Article 📅 2009 🏛 Springer Healthcare Communications 🌐 English ⚖ 240 KB

Analysis of PTEN and HIF-1α and correlat

Analysis of PTEN and HIF-1α and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-α

✍ Robert A. Figlin; Paul de Souza; David McDermott; Janice P. Dutcher; Anna Berken 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 324 KB

Effect of temsirolimus versus interferon

Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies

✍ Janice P. Dutcher; Paul de Souza; David McDermott; Robert A. Figlin; Anna Berken 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 253 KB

Health-related quality of life in patien

✍ Cella, D; Michaelson, M D; Bushmakin, A G; Cappelleri, J C; Charbonneau, C; Kim, 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 303 KB

Evaluation of deoxycoformycin in patient

Evaluation of deoxycoformycin in patients with advanced renal cell carcinoma

✍ Robert S. Witte; Christine Walsh; Hugh Fisher; Martin M. Okem; Douglas J. Reding 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 145 KB

Metastatic renal-cell carcinoma patients

Metastatic renal-cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon γ: Immunological monitoring

✍ Françoisc Farace; Marc Pallardy; Eric Angevin; Thierry Hercend; Bernard Escudier 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 737 KB

## Abstract We investigated the biological response of 73 patients with metastatic renal‐cell carcinoma (MRCC) treated by repetitive weekly cycles of high‐dose interleukin 2 (IL‐2) (protocol 1, 40 patients) or IL‐2 plus interferon‐gamma (IFN‐γ) (protocol 2, 33 patients). The objectives of this stud